ULK1 and amyotrophic lateral sclerosis: Consequently, pharmacological and genetic activation of ULK1 stimulates autophagy and reduces neurotoxicity in ALS models, providing a strong rationale for the development of ULK1-targeted therapies (Vahsen and Lingor, 2021; Liu et al., 2023).